Information Provided By:
Fly News Breaks for December 15, 2017
RIGL
Dec 15, 2017 | 07:14 EDT
Cantor Fitzgerald analyst Elemer Piros last night initiated Rigel Pharmaceuticals with an Overweight rating and $6 price target. The company is poised to achieve FDA approval of fostamatinib for lead indication immune thrombocytopenia, Piros tells investors in a research note. The analyst also believes fostamatinib has an attractive opportunity to expand its use with additional immune-related rare conditions autoimmune hemolytic anemia and immunoglobulin A nephropathy, both of which are in Phase 2 development.
News For RIGL From the Last 2 Days
There are no results for your query RIGL